Clearance of amyloid-β peptide across the blood-brain barrier: Implication for therapies in Alzheimer's disease

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 1, 2009, Pages 16-30

  Deane, Rashid ^a   Bell, R D ^a   Sagare, A ^a   Zlokovic, Berisiav V ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; FC RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MYOCARDIN; RECOMBINANT LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 4; RECOMBINANT PROTEIN; SERUM RESPONSE FACTOR; UNCLASSIFIED DRUG; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ANTIBODY; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN RECEPTOR;

ALZHEIMER DISEASE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BEHAVIOR; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; CARBOXY TERMINAL SEQUENCE; DRUG MECHANISM; DRUG PENETRATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOTHERAPY; LIGAND BINDING; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TRANSPORT; TIGHT JUNCTION; ANIMAL; IMMUNOLOGY; METABOLISM; METHODOLOGY; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; BLOOD-BRAIN BARRIER; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; LDL-RECEPTOR RELATED PROTEIN 1; RECEPTORS, FC; RECEPTORS, IMMUNOLOGIC;

EID: 65649105035     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709787601867     Document Type: Article

References (140)

1. Alzheimer, A.; Stelzmann, R.A.; Schnitzlein, H.N.; Murtagh, F.R. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin. Anat., 1995, 8(6), 429-31.
2. Alzheimer's Association. 2008 Alzheimer's disease Facts and Figures. http://www.alz.org/national/documents/report_alzfactsfigures2008.pdf (accessed Jan 16, 2009).
3. Kayed, R.; Head, E.; Thompson, J.L.; McIntire, T.M.; Milton, S.C.; Cotman, C.W.; Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 2003, 300(5618), 486-9.
4. Walsh, D.M.; Klyubin, I.; Shankar, G.M.; Townsend, M.; Fadeeva, J.V.; Betts, V.; Podlisny, M.B.; Cleary, J.P.; Ashe, K.H.; Rowan, M.J.; Selkoe, D.J. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem. Soc. Trans., 2005, 33(Pt 5), 1087-90.
5. Lesne, S.; Koh, M.T.; Kotilinek, L.; Kayed, R.; Glabe, C.G.; Yang, A.; Gallagher, M.; Ashe, K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature, 2006, 440(7082), 352-7.
6. Selkoe, D.J. Clearing the brain's amyloid cobwebs. Neuron, 2001, 32(2), 177-80.
7. Snyder, E.M.; Nong, Y.; Almeida, C.G.; Paul, S.; Moran, T.; Choi, E.Y.; Nairn, A.C.; Salter, M.W.; Lombroso, P.J.; Gouras, G.K.; Greengard, P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci., 2005, 8(8), 1051-8.
8. Tanzi, R.E.; Bertram, L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell, 2005, 120(4), 545-55.
9. Hardy, J. Amyloid double trouble. Nat. Genet., 2006, 38(1), 11-2.
10. Rovelet-Lecrux, A.; Hannequin, D.; Raux, G.; Le Meur, N.; Laquerriere, A.; Vital, A.; Dumanchin, C.; Feuillette, S.; Brice, A.; Vercelletto, M.; Dubas, F.; Frebourg, T.; Campion, D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet., 2006, 38(1), 24-6.
11. Holtzman, D.M.; Zlokovic, B.V. In Alzheimer's disease: advances in genetics, molecules and cellular biology; S. Sisodia; R. Tanzi, Eds.; Springer: New York, 2007; pp. 151-54.
12. Haass, C.; Selkoe, D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol., 2007, 8(2), 101-12.
13. Zlokovic, B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron, 2008, 57(2), 178-201.
14. Citron, M.; Oltersdorf, T.; Haass, C.; McConlogue, L.; Hung, A.Y.; Seubert, P.; Vigo-Pelfrey, C.; Lieberburg, I.; Selkoe, D.J. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature, 1992, 360(6405), 672-4.
15. Zlokovic, B.V.; Shinya, Y.; Holyzman, D.; Ghiso, J.; Frangione, B. Clearance of amyloid β-peptide from brain: transport or metaboloism. Nat. Med., 2000, 6, 718-719.
16. Tanzi, R.E.; Moir, R.D.; Wagner, S.L. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron, 2004, 43(5), 605-8.
17. Zlokovic, B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci., 2005, 28(4), 202-8.
18. Iadecola, C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci., 2004, 5(5), 347-60.
19. Zlokovic, B.V. Clearing amyloid through the blood-brain barrier. J. Neurochem., 2004, 89(4), 807-11.
20. Han, B.H.; Zhou, M.L.; Abousaleh, F.; Brendza, R.P.; Dietrich, H.H.; Koenigsknecht-Talboo, J.; Cirrito, J.R.; Milner, E.; Holtzman, D.M.; Zipfel, G.J. Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J. Neurosci., 2008, 28(50), 13542-50.
21. Deane, R.; Sagare, A.; Hamm, K.; Parisi, M.; Lane, S.; Finn, M.B.; Holtzman, D.M.; Zlokovic, B.V. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest., 2008, 118(12), 4002-13.
22. Bell, R.D.; Deane, R.; Chow, N.; Long, X.; Sagare, A.; Singh, I.; Streb, J.W.; Guo, H.; Rubio, A.; Van Nostrand, W.; Miano, J.M.; Zlokovic, B.V. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat. Cell Biol., 2008, 11(2), 143-153.
23. Ballatore, C.; Lee, V.M.; Trojanowski, J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci., 2007, 8(9), 663-72.
24. Deane, R.; Du Yan, S.; Submamaryan, R.K.; LaRue, B.; Jovanovic, S.; Hogg, E.; Welch, D.; Manness, L.; Lin, C.; Yu, J.; Zhu, H.; Ghiso, J.; Frangione, B.; Stern, A.; Schmidt, A.M.; Armstrong, D.L.; Arnold, B.; Liliensiek, B.; Nawroth, P.; Hofman, F.; Kindy, M.; Stern, D.; Zlokovic, B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med., 2003, 9(7), 907-13.
25. Shibata, M.; Yamada, S.; Kumar, S.R.; Calero, M.; Bading, J.; Frangione, B.; Holtzman, D.M.; Miller, C.A.; Strickland, D.K.; Ghiso, J.; Zlokovic, B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest., 2000, 106(12), 1489-99.
26. Deane, R.; Wu, Z.; Sagare, A.; Davis, J.; Du Yan, S.; Hamm, K.; Xu, F.; Parisi, M.; LaRue, B.; Hu, H.W.; Spijkers, P.; Guo, H.; Song, X.; Lenting, P.J.; Van Nostrand, W.E.; Zlokovic, B.V. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron, 2004, 43(3), 333-44.
27. Deane, R.; Wu, Z.; Zlokovic, B.V. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke, 2004, 35(Suppl 1), 2628-31.
28. Yan, S.D.; Chen, X.; Fu, J.; Chen, M.; Zhu, H.; Roher, A.; Slattery, T.; Zhao, L.; Nagashima, M.; Morser, J.; Migheli, A.; Nawroth, P.; Stern, D.; Schmidt, A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature, 1996, 382(6593), 685-91.
29. Donahue, J.E.; Flaherty, S.L.; Johanson, C.E.; Duncan, J.A., 3rd.; Silverberg, G.D.; Miller, M.C.; Tavares, R.; Yang, W.; Wu, Q.; Sabo, E.; Hovanesian, V.; Stopa, E.G. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol., 2006, 112(4), 405-15.
30. Miles, M.C.; Tavares, R.; Johanson, C.E.; Hovanesian, V.; Donahue, J.E.; Gonzalez, L.; Silverberg, G.D.; Stopa, E.G. Hippocampus RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res., 2008, 1230, 273-80.
31. Zlokovic, B.V.; Yamada, S.; Holtzman, D.; Ghiso, J.; Frangione, B. Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat. Med., 2000, 6(7), 718-9.
32. Smith, D.E.; Johanson, C.E.; Keep, R.F. Peptide and peptide analog transport systems at the blood-CSF barrier. Adv. Drug Deliv. Rev., 2004, 56(12), 1765-91.
33. Redzic, Z.B.; Segal, M.B. The structure of the choroid plexus and the physiology of the choroid plexus epithelium. Adv. Drug Deliv. Rev., 2004, 56(12), 1695-716.
34. Zhang, S.; Murphy, T.H. Imaging the impact of cortical microcirculation on synaptic structure and sensory-evoked hemodynamic responses in vivo. PLoS Biol., 2007, 5(5), e119.
35. Fagan, A.M.; Mintun, M.A.; Mach, R.H.; Lee, S.Y.; Dence, C.S.; Shah, A.R.; LaRossa, G.N.; Spinner, M.L.; Klunk, W.E.; Mathis, C.A.; DeKosky, S.T.; Morris, J.C.; Holtzman, D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol., 2006, 59(3), 512-9.
36. Biere, A.L.; Ostaszewski, B.; Stimson, E.R.; Hyman, B.T.; Maggio, J.E.; Selkoe, D.J. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J. Biol. Chem., 1996, 271(51), 32916-22.
37. Martel, C.L.; Mackic, J.B.; Matsubara, E.; Governale, S.; Miguel, C.; Miao, W.; McComb, J.G.; Frangione, B.; Ghiso, J.; Zlokovic, B.V. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. J Neurochem., 1997, 69(5), 1995-2004.
38. Tokuda, T.; Calero, M.; Matsubara, E.; Vidal, R.; Kumar, A.; Permanne, B.; Zlokovic, B.; Smith, J.D.; Ladu, M.J.; Rostagno, A.; Frangione, B.; Ghiso, J. Lipidation of apolipoprotein E influences it isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem. J., 2000, 348(Pt 2), 359-65.
39. Calero, M.; Rostagno, A.; Matsubara, E.; Zlokovic, B.; Frangione, B.; Ghiso, J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc. Res. Tech., 2000, 50(4), 305-15.
40. Sousa, J.C.; Cardoso, I.; Marques, F.; Saraiva, M.J.; Palha, J.A. Transthyretin and Alzheimer's disease: where in the brain? Neurobiol. Aging, 2007, 28(5), 713-8.
41. Narita, M.; Holtzman, D.M.; Schwartz, A.L.; Bu, G. Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J. Neurochem., 1997, 69(5), 1904-11.
42. Sagare, A.; Deane, R.; Bell, R.D.; Johnson, B.; Hamm, K.; Pendu, R.; Marky, A.; Lenting, P.J.; Wu, Z.; Zarcone, T.; Goate, A.; Mayo, K.; Perlmutter, D.; Coma, M.; Zhong, Z.; Zlokovic, B.V. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med., 2007, 13(9), 1029-31.
43. Zlokovic, B.V.; Martel, C.L.; Matsubara, E.; McComb, J.G.; Zheng, G.; McCluskey, R.T.; Frangione, B.; Ghiso, J. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Natl. Acad. Sci. U. S. A., 1996, 93(9), 4229-34.
44. Bell, R.D.; Sagare, A.P.; Friedman, A.E.; Bedi, G.S.; Holtzman, D.M.; Deane, R.; Zlokovic, B.V. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab., 2007, 27(5), 909-18.
45. Wati, H.; Kawarabayashi, T.; Matsubara, E.; Kasai, A.; Hirasawa, T.; Kubota, T.; Harigaya, Y.; Shoji, M.; Maeda, S. Transthyretin accelerates vascular Abeta deposition in a mouse model of Alzheimer's disease. Brain Pathol., 2009, 19(1), 48-57.
46. Zlokovic, B.V. Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. Life Sci., 1996, 59(18), 1483-97.
47. Kanekiyo, T.; Ban, T.; Aritake, K.; Huang, Z.L.; Qu, W.M.; Okazaki, I.; Mohri, I.; Murayama, S.; Ozono, K.; Taniike, M.; Goto, Y.; Urade, Y. Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid. Proc. Natl. Acad. Sci. U. S. A., 2007, 104(15), 6412-7.
48. Silverberg, G.D.; Mayo, M.; Saul, T.; Rubenstein, E.; McGuire, D. Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol., 2003, 2(8), 506-11.
49. Zlokovic, B.V.; Ghiso, J.; Mackic, J.B.; McComb, J.G.; Weiss, M.H.; Frangione, B. Blood-brain barrier transport of circulating Alzheimer's amyloid beta. Biochem. Biophys. Res. Commun., 1993, 197(3), 1034-40.
50. Maness, L.M.; Banks, W.A.; Podlisny, M.B.; Selkoe, D.J.; Kastin, A.J. Passage of human amyloid beta-protein 1-40 across the murine blood-brain barrier. Life Sci., 1994, 55(21), 1643-50.
51. Martel, C.L.; Mackic, J.B.; McComb, J.G.; Ghiso, J.; Zlokovic, B.V. Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid beta in guinea pigs. Neurosci. Lett., 1996, 206(2-3), 157-60.
52. Mackic, J.B.; Weiss, M.H.; Miao, W.; Kirkman, E.; Ghiso, J.; Calero, M.; Bading, J.; Frangione, B.; Zlokovic, B.V. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J. Neurochem., 1998, 70(1), 210-5.
53. Mackic, J.B.; Stins, M.; McComb, J.G.; Calero, M.; Ghiso, J.; Kim, K.S.; Yan, S.D.; Stern, D.; Schmidt, A.M.; Frangione, B.; Zlokovic, B.V. Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J. Clin. Invest., 1998, 102(4), 734-43.
54. Mackic, J.B.; Bading, J.; Ghiso, J.; Walker, L.; Wisniewski, T.; Frangione, B.; Zlokovic, B.V. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vasc. Pharmacol., 2002, 38(6), 303-13.
55. LaRue, B.; Hogg, E.; Sagare, A.; Jovanovic, S.; Maness, L.; Maurer, C.; Deane, R.; Zlokovic, B.V. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice. J. Neurosci. Meth., 2004, 138(1-2), 233-42.
56. Clifford, P.M.; Zarrabi, S.; Siu, G.; Kinsler, K.J.; Kosciuk, M.C.; Venkataraman, V.; D'Andrea, M.R.; Dinsmore, S.; Nagele, R.G. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res., 2007, 1142, 223-36.
57. Zlokovic, B.V.; Banks, W.A.; el Kadi, H.; Erchegyi, J.; Mackic, J.B.; McComb, J.G.; Kastin, A.J. Transport, uptake, and metabolism of blood-borne vasopressin by the blood-brain barrier. Brain Res., 1992, 590(1-2), 213-8.
58. Zlokovic, B.V.; Mackic, J.B.; Djuricic, B.; Davson, H. Kinetic analysis of leucine-enkephalin cellular uptake at the luminal side of the blood-brain barrier of an in situ perfused guinea-pig brain. J. Neurochem., 1989, 53(5), 1333-40.
59. Zlokovic, B.V.; Begley, D.J.; Chain-Eliash, D.G. Blood-brain barrier permeability to leucine-enkephalin, D-alanine2-D-leucine5-enkephalin and their N-terminal amino acid (tyrosine). Brain Res., 1985, 336(1), 125-32.
60. Deane, R.; LaRue, B.; Sagare, A.P.; Castellino, F.J.; Zhong, Z.; Zlokovic, B.V. Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier. J. Cereb. Blood Flow Metab., 2009, 29(1), 25-33.
61. Zlokovic, B.V.; Skundric, D.S.; Segal, M.B.; Lipovac, M.N.; Mackic, J.B.; Davson, H. A saturable mechanism for transport of immunoglobulin G across the blood-brain barrier of the guinea pig. Exp. Neurol., 1990, 107(3), 263-70.
62. Segal, M.B.; Preston, J.E.; Collis, C.S.; Zlokovic, B.V. Kinetics and Na independence of amino acid uptake by blood side of perfused sheep choroid plexus. Am. J. Physiol., 1990, 258(5 Pt 2), F1288-94.
63. Deane, R.; Zlokovic, B.V. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr. Alzheimer Res., 2007, 4(2), 191-7.
64. Deane, R.; Sagare, A.; Zlokovic, B.V. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr. Pharm. Des., 2008, 14(16), 1601-5.
65. Hofmann, M.A.; Drury, S.; Fu, C.; Qu, W.; Taguchi, A.; Lu, Y.; Avila, C.; Kambham, N.; Bierhaus, A.; Nawroth, P.; Neurath, M.F.; Slattery, T.; Beach, D.; McClary, J.; Nagashima, M.; Morser, J.; Stern, D.; Schmidt, A.M. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell, 1999, 97(7), 889-901.
66. Kislinger, T.; Fu, C.; Huber, B.; Qu, W.; Taguchi, A.; Du Yan, S.; Hofmann, M.; Yan, S.F.; Pischetsrieder, M.; Stern, D.; Schmidt, A.M. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem., 1999, 274(44), 31740-9.
67. Stern, D.; Yan, S.D.; Yan, S.F.; Schmidt, A.M. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv. Drug Deliv. Rev., 2002, 54(12), 1615-25.
68. Giri, R.; Shen, Y.; Stins, M.; Du Yan, S.; Schmidt, A.M.; Stern, D.; Kim, K.S.; Zlokovic, B.; Kalra, V.K. beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am. J. Physiol. Cell Physiol., 2000, 279(6), C1772-81.
69. Shayo, M.; McLay, R.N.; Kastin, A.J.; Banks, W.A. The putative blood-brain barrier transporter for the beta-amyloid binding protein apolipoprotein j is saturated at physiological concentrations. Life Sci., 1997, 60(7), PL115-8.
70. Pfizer, ClinicalTrials.gov: A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease. http://clinicaltrials.gov/ct2/show/NCT00566397?term=RAGE&rank=2 (accessed Jan 16, 2009).
71. Deane, R.; Perry, S.; Sagare, A.; Cheng, T.; LaRue, B.; Miller, B.; Zlokovic, B. Tertiary amides block RAGE-mediated Aβ transport into brain in a mouse model of AD. Program No. 412.3. 2006, Society for Neuroscience Meeting Planner, Alanta, GA.
72. Deane, R.; Sagare, A.; Paquette, N.; Bell, R.; LaRue, B.; Ross, N.; Miller, B.; Zlokovic, B. Tertiary amides improves cerebral blood flow and behavioral performance in a mouse model of AD by blocking RAGE/ Aβ interaction. Program No. 704.3. 2008, Society for Neuroscience Meeting Planner, Washington, DC.
73. Herz, J. The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron, 2001, 29(3), 571-81.
74. Herz, J.; Strickland, D.K. LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest., 2001, 108(6), 779-84.
75. Willnow, T.E.; Rohlmann, A.; Horton, J.; Otani, H.; Braun, J.R.; Hammer, R.E.; Herz, J. RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors. EMBO J., 1996, 15(11), 2632-9.
76. Meijer, A.B.; Rohlena, J.; van der Zwaan, C.; van Zonneveld, A.J.; Boertjes, R.C.; Lenting, P.J.; Mertens, K. Functional duplication of ligand-binding domains within low-density lipoprotein receptor-related protein for interaction with receptor associated protein, alpha2-macroglobulin, factor IXa and factor VIII. Biochim. Biophys. Acta., 2007, 1774(6), 714-22.
77. Obermoeller-McCormick, L.M.; Li, Y.; Osaka, H.; FitzGerald, D.J.; Schwartz, A.L.; Bu, G. Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptor-related protein. J. Cell Sci., 2001, 114(Pt 5), 899-908.
78. Benchenane, K.; Berezowski, V.; Fernandez-Monreal, M.; Brillault, J.; Valable, S.; Dehouck, M.P.; Cecchelli, R.; Vivien, D.; Touzani, O.; Ali, C. Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process. Stroke, 2005, 36(5), 1065-70.
79. Li, Y.; Lu, W.; Marzolo, M. P.; Bu, G. Differential functions of members of the low density lipoprotein receptor family suggested by their distinct endocytosis rates. J. Biol. Chem., 2001, 276(21), 18000-6.
80. Trommsdorff, M.; Borg, J.P.; Margolis, B.; Herz, J. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J. Biol. Chem., 1998, 273(50), 33556-60.
81. Gotthardt, M.; Trommsdorff, M.; Nevitt, M.F.; Shelton, J.; Richardson, J.A.; Stockinger, W.; Nimpf, J.; Herz, J. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J. Biol. Chem., 2000, 275(33), 25616-24.
82. van der Geer, P. Phosphorylation of LRP1: regulation of transport and signal transduction. Trends Cardiovasc. Med., 2002, 12(4), 160-5.
83. Bu, G.; Sun, Y.; Schwartz, A.L.; Holtzman, D.M. Nerve growth factor induces rapid increases in functional cell surface low density lipoprotein receptor-related protein. J. Biol. Chem., 1998, 273(21), 13359-65.
84. Kang, D.E.; Saitoh, T.; Chen, X.; Xia, Y.; Masliah, E.; Hansen, L.A.; Thomas, R.G.; Thal, L.J.; Katzman, R. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology, 1997, 49(1), 56-61.
85. Lambert, J.C.; Wavrant-De Vrieze, F.; Amouyel, P.; Chartier-Harlin, M.C. Association at LRP gene locus with sporadic late-onset Alzheimer's disease. Lancet, 1998, 351(9118), 1787-8.
86. Wavrant-DeVrieze, F.; Lambert, J.C.; Stas, L.; Crook, R.; Cottel, D.; Pasquier, F.; Frigard, B.; Lambrechts, M.; Thiry, E.; Amouyel, P.; Tur, J.P.; Chartier-Harlin, M.C.; Hardy, J.; Van Leuven, F. Association between coding variability in the LRP gene and the risk of late-onset Alzheimer's disease. Hum. Genet., 1999, 104(5), 432-4.
87. Christoforidis, M.; Schober, R.; Krohn, K. Genetic-morphologic association study: association between the low density lipoprotein-receptor related protein (LRP) and cerebral amyloid angiopathy. Neuropathol. Appl. Neurobiol., 2005, 31(1), 11-9.
88. Bertram, L.; Blacker, D.; Crystal, A.; Mullin, K.; Keeney, D.; Jones, J.; Basu, S.; Yhu, S.; Guenette, S.; McInnis, M.; Go, R.; Tanzi, R. Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies. Exp. Gerontol., 2000, 35, 1353-61.
89. Rebeck, G.W.; Harr, S.D.; Strickland, D.K.; Hyman, B.T. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/ low-density-lipoprotein receptor-related protein. Ann. Neurol., 1995, 37(2), 211-7.
90. Arelin, K.; Kinoshita, A.; Whelan, C.M.; Irizarry, M.C.; Rebeck, G.W.; Strickland, D.K.; Hyman, B.T. LRP and senile plaques in Alzheimer's disease: colocalization with apolipoprotein E and with activated astrocytes. Brain Res. Mol. Brain Res., 2002, 104(1), 38-46.
91. Pietrzik, C.U.; Yoon, I.S.; Jaeger, S.; Busse, T.; Weggen, S.; Koo, E.H. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J. Neurosci., 2004, 24, 4259-65.
92. Waldron, E.; Heilig, C.; Schweitzer, A.; Nadella, N.; Jaeger, S.; Martin, A.M.; Weggen, S.; Brix, K.; Pietrzik, C.U. LRP1 modulates APP trafficking along early compartments of the secretory pathway. Neurobiol. Dis., 2008, 31, 188-97.
93. Qiu, Z.; Strickland, D.K.; Hyman, B.T.; Rebeck, G.W. Alpha2-macroglobulin enhances the clearance of endogenous soluble beta-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. J. Neurochem., 1999, 73(4), 1393-8.
94. DeMattos, R.B.; Cirrito, J.R.; Parsadanian, M.; May, P.C.; O'Dell, M.A.; Taylor, J.W.; Harmony, J.A.; Aronow, B.J.; Bales, K.R.; Paul, S.M.; Holtzman, D.M. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron, 2004, 41(2), 193-202.
95. Zerbinatti, C.V.; Bu, G. LRP and Alzheimer's disease. Rev. Neurosci., 2005, 16(2), 123-35.
96. Zerbinatti, C.V.; Wozniak, D.F.; Cirrito, J.; Cam, J.A.; Osaka, H.; Bales, K.R.; Zhuo, M.; Paul, S.M.; Holtzman, D.M.; Bu, G. Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc. Natl. Acad. Sci. USA, 2004, 101(4), 1075-80.
97. Bading, J.R.; Yamada, S.; Mackic, J.B.; Kirkman, L.; Miller, C.; Calero, M.; Ghiso, J.; Frangione, B.; Zlokovic, B.V. Brain clearance of Alzheimer's amyloid-beta40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J. Drug Target, 2002, 10(4), 359-68.
98. Cirrito, J.R.; Deane, R.; Fagan, A.M.; Spinner, M.L.; Parsadanian, M.; Finn, M.B.; Jiang, H.; Prior, J.L.; Sagare, A.; Bales, K.R.; Paul, S.M.; Zlokovic, B.V.; Piwnica-Worms, D.; Holtzman, D.M. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest., 2005, 115(11), 3285-90.
99. Shiiki, T.; Ohtsuki, S.; Kurihara, A.; Naganuma, H.; Nishimura, K.; Tachikawa, M.; Hosoya, K.; Terasaki, T. Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J. Neurosci., 2004, 24(43), 9632-7.
100. Monro, O.R.; Mackic, J.B.; Yamada, S.; Segal, M.B.; Ghiso, J.; Maurer, C.; Calero, M.; Frangione, B.; Zlokovic, B.V. Substitution at codon 22 reduces clearance of Alzheimer's amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol. Aging, 2002, 23(3), 405-12.
101. Davis, J.; Xu, F.; Deane, R.; Romanov, G.; Previti, M.L.; Zeigler, K.; Zlokovic, B.V.; Van Nostrand, W.E. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J. Biol. Chem., 2004, 279(19), 20296-306.
102. Yamada, K.; Hashimoto, T.; Yabuki, C.; Nagae, Y.; Tachikawa, M.; Strickland, D.K.; Liu, Q.; Bu, G.; Basak, J.M.; Holtzman, D.M.; Ohtsuki, S.; Terasaki, T.; Iwatsubo, T. The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells. J. Biol. Chem., 2008, 283(50), 34554-62.
103. Bu, G. The roles of receptor-associated protein (RAP) as a molecular chaperone for members of the LDL receptor family. Int. Rev. Cytol., 2001, 209, 79-116.
104. Nazer, B.; Hong, S.; Selkoe, D.J. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol. Dis., 2008, 30(1), 94-102.
105. Wu, Z.; Guo, H.; Chow, N.; Sallstrom, J.; Bell, R.D.; Deane, R.; Brooks, A.I.; Kanagala, S.; Rubio, A.; Sagare, A.; Liu, D.; Li, F.; Armstrong, D.; Gasiewicz, T.; Zidovetzki, R.; Song, X.; Hofman, F.; Zlokovic, B.V. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat. Med., 2005, 11(9), 959-65.
106. Chow, N.; Bell, R.D.; Deane, R.; Streb, J.W.; Chen, J.; Brooks, A.; Van Nostrand, W.; Miano, J.M.; Zlokovic, B.V. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proc. Natl. Acad. Sci. USA, 2007, 104(3), 823-8.
107. Tamaki, C.; Ohtsuki, S.; Iwatsubo, T.; Hashimoto, T.; Yamada, K.; Yabuki, C.; Terasaki, T. Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm. Res., 2006, 23(7), 1407-16.
108. Tamaki, C.; Ohtsuki, S.; Terasaki, T. Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol. Pharmacol., 2007, 72(4), 850-5.
109. Brody, D.L.; Holtzman, D.M. Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci., 2008, 31, 175-93.
110. Boche, D.; Nicoll, J.A. The role of the immune system in clearance of Abeta from the brain. Brain Pathol., 2008, 18(2), 267-78.
111. Selkoe, D.J.; Schenk, D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 545-84.
112. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400(6740), 173-7.
113. Morgan, D.; Diamond, D.M.; Gottschall, P.E.; Ugen, K.E.; Dickey, C.; Hardy, J.; Duff, K.; Jantzen, P.; DiCarlo, G.; Wilcock, D.; Connor, K.; Hatcher, J.; Hope, C.; Gordon, M.; Arendash, G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408(6815), 982-5.
114. Janus, C.; Pearson, J.; McLaurin, J.; Mathews, P.M.; Jiang, Y.; Schmidt, S.D.; Chishti, M.A.; Horne, P.; Heslin, D.; French, J.; Mount, H.T.; Nixon, R.A.; Mercken, M.; Bergeron, C.; Fraser, P.E.; St George-Hyslop, P.; Westaway, D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 2000, 408(6815), 979-82.
115. Das, P.; Howard, V.; Loosbrock, N.; Dickson, D.; Murphy, M.P.; Golde, T.E. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J. Neurosci., 2003, 23(24), 8532-8.
116. Lemere, C.A.; Spooner, E.T.; LaFrancois, J.; Malester, B.; Mori, C.; Leverone, J.F.; Matsuoka, Y.; Taylor, J.W.; DeMattos, R.B.; Holtzman, D.M.; Clements, J.D.; Selkoe, D.J.; Duff, K.E. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol. Dis., 2003, 14(1), 10-8.
117. Sigurdsson, E.M.; Scholtzova, H.; Mehta, P.D.; Frangione, B.; Wisniewski, T. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol., 2001, 159(2), 439-47.
118. Dodart, J.C.; Bales, K.R.; Gannon, K.S.; Greene, S.J.; DeMattos, R.B.; Mathis, C.; DeLong, C.A.; Wu, S.; Wu, X.; Holtzman, D.M.; Paul, S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci., 2002, 5(5), 452-7.
119. Kotilinek, L.A.; Bacskai, B.; Westerman, M.; Kawarabayashi, T.; Younkin, L.; Hyman, B.T.; Younkin, S.; Ashe, K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci., 2002, 22(15), 6331-5.
120. Wilcock, D.M.; DiCarlo, G.; Henderson, D.; Jackson, J.; Clarke, K.; Ugen, K.E.; Gordon, M.N.; Morgan, D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci., 2003, 23(9), 3745-51.
121. Head, E.; Pop, V.; Vasilevko, V.; Hill, M.; Saing, T.; Sarsoza, F.; Nistor, M.; Christie, L.A.; Milton, S.; Glabe, C.; Barrett, E.; Cribbs, D. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J. Neurosci., 2008, 28(14), 3555-66.
122. Lemere, C.A.; Beierschmitt, A.; Iglesias, M.; Spooner, E.T.; Bloom, J.K.; Leverone, J.F.; Zheng, J.B.; Seabrook, T.J.; Louard, D.; Li, D.; Selkoe, D.J.; Palmour, R.M.; Ervin, F.R. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am. J. Pathol., 2004, 165(1), 283-97.
123. Trouche, S.G.; Asuni, A.; Rouland, S.; Wisniewski, T.; Frangione, B.; Verdier, J.M.; Sigurdsson, E.M.; Mestre-Frances, N. Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives. Vaccine, 2008, advance online publication: doi:10.1016/j.vaccine.2008. 12.012, Dec. 27, 2008.
124. Pfeifer, M.; Boncristiano, L.; Bondolfi, L.; Stalder, A.; Deller, T.; Staufenbiel, M.; Mathews, P.M.; Jucker, M. Cerebral hemorrage after passice anti-Abeta immunotherapy. Science, 2002, 298(5597), 1379.
125. Racke, M.M.; Boone, L.I.; Hepburn, D.L.; Pasadainian, M.; Bryan, M.T.; Ness, D.K.; Pioroozi, K.S.; Jordon, W.H.; Brown, D.D.; Hoffman, W.P.; Holtzman, D.M.; Bales, K.R.; Gitter, B.D.;May, P.C.; Paul, S.M.; Demattos, R.B. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci., 2005, 25(3), 629-36.
126. Orgogozo, J.M.; Gilman, S.; Dartigues, J.F.; Laurent, B.; Puel, M.; Kirby, L.C.; Jouanny, P.; Dubois, B.; Eisner, L.; Flitman, S.; Michel, B.F.; Boada, M.; Frank, A.; Hock, C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 2003, 61(1), 46-54.
127. DeMattos, R.B.; Bales, K.R.; Cummins, D.J.; Dodart, J.C.; Paul, S.M.; Holtzman, D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2001, 98(15), 8850-5.
128. DeMattos, R.B.; Bales, K.R.; Cummins, D.J.; Paul, S.M.; Holtzman, D.M. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science, 2002, 295(5563), 2264-7.
129. Deane, R.; Sagare, A.; Hamm, K.; Parisi, M.; LaRue, B.; Guo, H.; Wu, Z.; Holtzman, D.M.; Zlokovic, B.V. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J. Neurosci., 2005, 25(50), 11495-503.
130. Matsuoka, Y.; Saito, M.; LaFrancois, J.; Saito, M.; Gaynor, K.; Olm, V.; Wang, L.; Casey, E.; Lu, Y.; Shiratori, C.; Lemere, C.; Duff, K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci., 2003, 23(1), 29-33.
131. Balin, B.J.; Broadwell, R.D.; Salcman, M.; el-Kalliny, M. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J. Comp. Neurol., 1986, 251(2), 260-80.
132. Broadwell, R.D.; Sofroniew, M.V. Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system. Exp. Neurol., 1993, 120(2), 245-63.
133. Banks, W.A.; Terrell, B.; Farr, S.A.; Robinson, S.M.; Nonaka, N.; Morley, J.E. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides, 2002, 23(12), 2223-6.
134. Bard, F.; Cannon, C.; Barbour, R.; Burke, R.L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Lieberburg, I.; Motter, R.; Nguyen, M.; Soriano, F.; Vasquez, N.; Weiss, K.; Welch, B.; Seubert, P.; Schenk, D.; Yednock, T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 2000, 6(8), 916-9.
135. Koenigsknecht-Talboo, J.; Meyer-Luehmann, M.; Parsadanian, M.; Garcia-Alloza, M.; Finn, M.B.; Hyman, B.T.; Bacskai, B.J.; Holtzman, D.M. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J. Neurosci., 2008, 28(52), 14156-64.
136. Bacskai, B.J.; Kajdasz, S.T.; McLellan, M.E.; Games, D.; Seubert, P.; Schenk, D.; Hyman, B.T. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci., 2002, 22(18), 7873-8.
137. Schlachetzki, F.; Zhu, C.; Pardridge, W.M. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J. Neurochem., 2002, 81(1), 203-6.
138. Roopenian, D.C.; Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol., 2007, 7(9), 715-25.
139. Vasilevko, V.; Xu, F.; Previti, M.L.; Van Nostrand, W.E.; Cribbs, D.H. Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice. J. Neurosci., 2007, 27(49), 13376-83.
140. Bacskai, B J.; Kajdasz, S.T.; Christie, R.H.; Carter, C.; Games, D.; Seubert, P.; Schenk, D.; Hyman, B.T. Imaging of amyloid-beta deposits in brains of lining mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med., 2001, 7(3), 369-72.